메토트렉세이트 치료에 실패한 류마티스관절염 환자에서 에타너셉트 사용에 대한 비용-효과 분석

• 영문명: Cost-Effectiveness Analysis of Etanercept in the Treatment of Methotrexate-resistant Rheumatoid Arthritis
• 발행기관: 대한약학회
• 저자명: 김종주(Jong Joo Kim) 박은자(Eun Ja Park) 박세정(Se Jung Park) 성윤경(Yun Kyung Sung) 배상철(Sang Cheol Bae) 이의경(Eui Kyung Lee)
• 간행물 정보: 『약학회지』제50권 제2호 (2006년), 70~77쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2006.04.30

영문 초록

A cost effective analysis was performed for comparing leflunomide + methotrexate. etanercent monotherapy and etanercept + methtrexate for 6 months. For the patients with methotrexate-resistant RA, ACR20 data were extracted from the published clinical trials searched from Pubmed. The direct medical cost was estimated based on ACR guideline and Korean National Health Insurance reimbursement. Combination therapy of etanercept + methotrexate was found to be more cost-effective than etanercept monotherapy, which meant it was a better therapeutic strategy for methotrexate-resistant RA.

키워드

rheumatoid arthritis cost-effectiveness analysis pharmacoeconomics etanercept